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A bs tr ac t
Background
Corticotropin-independent Cushing’s syndrome is caused by tumors or hyperplasia 
of the adrenal cortex. The molecular pathogenesis of cortisol-producing adrenal 
adenomas is not well understood.
Methods
We performed exome sequencing of tumor-tissue specimens from 10 patients with 
cortisol-producing adrenal adenomas and evaluated recurrent mutations in candi-
date genes in an additional 171 patients with adrenocortical tumors. We also per-
formed genomewide copy-number analysis in 35 patients with cortisol-secreting 
bilateral adrenal hyperplasias. We studied the effects of these genetic defects both 
clinically and in vitro.
Results
Exome sequencing revealed somatic mutations in PRKACA, which encodes the cata-
lytic subunit of cyclic AMP–dependent protein kinase (protein kinase A [PKA]), in 
8 of 10 adenomas (c.617A→C in 7 and c.595_596insCAC in 1). Overall, PRKACA so-
matic mutations were identified in 22 of 59 unilateral adenomas (37%) from patients 
with overt Cushing’s syndrome; these mutations were not detectable in 40 patients 
with subclinical hypercortisolism or in 82 patients with other adrenal tumors. 
Among 35 patients with cortisol-producing hyperplasias, 5 (including 2 first-degree 
relatives) carried a germline copy-number gain (duplication) of the genomic region on 
chromosome 19 that includes PRKACA. In vitro studies showed impaired inhibition 
of both PKA catalytic subunit mutants by the PKA regulatory subunit, whereas cells 
from patients with germline chromosomal gains showed increased protein levels of 
the PKA catalytic subunit; in both instances, basal PKA activity was increased.
Conclusions
Genetic alterations of the catalytic subunit of PKA were found to be associated with 
human disease. Germline duplications of this gene resulted in bilateral adrenal hyper-
plasias, whereas somatic PRKACA mutations resulted in unilateral cortisol-producing 
adrenal adenomas. (Funded by the European Commission Seventh Framework 
Program and others.)
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Endogenous hypercortisolism, referred to as Cushing’s syndrome, is associated with substantial morbidity and mortality.1 When 
Cushing’s syndrome is severe, patients have cata-
bolic symptoms such as muscle weakness, skin 
fragility, osteoporosis, and severe metabolic se-
quelae.2 Hypersecretion of cortisol can be driven 
by an excess of pituitary or ectopic corticotropin 
or can be due to adrenocortical tumors or hyper-
plasias with corticotropin-independent cortisol 
production. Adrenal adenomas are common, with 
a prevalence of at least 3% among persons older 
than 50 years of age.3 Whereas only a subset of 
these tumors is associated with overt Cushing’s 
syndrome, some degree of cortisol excess is pres-
ent, depending on the diagnostic criteria applied,4 
in up to 47% of patients with adrenal adenomas 
and is associated with a range of phenotypes, 
from hypertension to the metabolic syndrome 
and osteoporosis.5
The molecular pathogenesis of cortisol- producing 
adrenal adenomas is not well understood. Whereas 
somatic mutations in the gene encoding beta-
catenin (CTNNB1) have been found primarily in 
nonsecreting adrenocortical adenomas,6 there is 
some evidence that increased endocrine activity 
may be linked to aberrant cyclic AMP (cAMP) 
signaling.7,8 For instance, ectopic expression of 
G-protein–coupled receptors for neuroendocrine 
hormones or neurotransmitters that mediate 
their effects through cAMP has been implicated 
in syndromes such as food-dependent hypercor-
tisolism and related conditions9,10 that are caused 
by cortisol-producing adenomas or bilateral hyper-
plasias of the adrenal cortex. Moreover, somatic 
mutations in the gene encoding the α subunit of 
the stimulatory G protein (GNAS1) cause adenomas 
or hyperplasias leading to Cushing’s syndrome in 
patients with McCune–Albright syndrome11 or 
macronodular hyperplasia.12,13 Finally, mutations 
in the genes encoding the cAMP-degrading phos-
phodiesterase 11A (PDE11A)14 and phosphodiester-
ase 8B (PDE8B)15 and in the gene encoding the 
regulatory subunit of the cAMP-dependent pro-
tein kinase (protein kinase A [PKA]) (PRKAR1A)16,17 
have been identified in patients with Cushing’s 
syndrome due to primary pigmented nodular 
adrenocortical disease and in a small number of 
cortisol-producing adrenal adenomas. These ge-
netic alterations, however, explain only a small 
fraction of cases. The observation that a subset 
of adrenal adenomas is characterized by abnor-
mal PKA activity, despite the absence of muta-
tions in these candidate genes,18 suggests yet un-
known alterations in the cAMP–PKA signaling 
cascade in these tumors.
Me thods
Study Patients and DNA Extraction
Patients were recruited at three centers that par-
ticipate in the European Network for the Study 
of Adrenal Tumors and at the U.S. National Insti-
tutes of Health. We evaluated 139 patients with 
adrenal adenoma, 42 patients with adrenocortical 
carcinoma, and 35 patients with corticotropin-
independent bilateral adrenal hyperplasia who 
did not have germline mutations in PRKAR1A, 
PDE11A, or PDE8B or somatic GNAS mutations 
(33 with micronodular hyperplasia [31 with pri-
mary pigmented nodular adrenocortical disease 
and 2 with isolated micronodular adrenocortical 
disease] and 2 with macronodular hyperplasia) 
(Fig. S1 and Table S1 in the Supplementary Ap pen-
dix, available with the full text of this article at 
NEJM.org). In all cases, the diagnosis was histo-
logically confirmed after surgical resection. All 
the patients gave written informed consent, and 
the study was approved by the ethics committee 
at each participating institution.
The diagnosis of corticotropin-independent 
Cushing’s syndrome was based on a combination 
of biochemical hallmarks of hypercortisolism — 
elevated urinary excretion of free cortisol, increased 
late-night salivary or serum cortisol levels, sup-
pressed plasma corticotropin levels (<10 pg per 
milliliter [<2.2 pmol per liter]), and nonsuppress-
ible serum cortisol levels (>5 μg per deciliter 
[>138 nmol per liter]) after the administration of 
1 mg of dexamethasone — as well as on the 
presence of catabolic signs of hypercortisolism. 
Patients were classified as having overt Cushing’s 
syndrome if they had at least three abnormal 
biochemical test results or if they had typical 
catabolic features (i.e., muscle weakness, skin fra-
gility, and osteoporosis) plus at least two abnormal 
biochemical test results. Patients were considered 
to have endocrine-inactive adrenal lesions if they 
had normal biochemical test results and no cata-
bolic signs. All patients who had no catabolic 
signs but had at least one abnormal result in the 
abovementioned tests were classified as having 
subclinical Cushing’s syndrome.
DNA was extracted as described previously19-21 
from unilateral adrenocortical tumors in 181 
patients and from corresponding normal tissue 
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in 26 of these patients. Furthermore, germline 
DNA was available for all 35 patients with bi-
lateral hyperplasia, and DNA from adrenal-tissue 
samples obtained during surgery was available 
for 10 of these 35 patients.
Exome and PRKACA Sequencing
Exomes were enriched in solution and indexed 
with the use of the SureSelect XT Human All 
Exon 50Mb kit, version 4 (Agilent Technologies). 
Sequencing was performed as paired-end reads 
of 100 bp on HiSeq2000 systems (Illumina). 
Pools of 12 indexed libraries were sequenced on 
four lanes. Image analysis and base calling were 
performed with the use of Real-Time Analysis 
software (Illumina). Methods of variant detec-
tion and PRKACA sequencing are described in the 
Supplementary Appendix.
Comparative Genomic Hybridization
Array-based comparative genomic hybridization 
analysis was performed with the use of commer-
cial arrays (Agilent Technologies), according to 
the manufacturer’s instructions and as described 
previously.22 Technical details are provided in the 
Supplementary Appendix.
In Silico Analysis of Human Mutations
Structural images were prepared with the use of 
PyMOL software (www.pymol.org). The structure 
of the mouse full-length tetrameric RIIβ(2):Cα(2) 
holoenzyme23 (Protein Data Bank entry 3TNP) 
was used to display the structures of the PKA cat-
alytic subunit (Cα) and regulatory subunit (RIIβ).
DNA Constructs and Site-Directed Mutagenesis
Plasmids encoding nonmutant human RIIβ or Cα 
subunits were purchased from OriGene Tech nolo-
gies. The PRKACA-containing plasmid was used for 
site-directed mutagenesis, with the c.617A→C and 
the c.595_596insCAC mutation introduced with 
the use of the QuikChange II Site-Directed Muta-
genesis Kit (Agilent Technologies), according to 
the manufacturer’s protocol. The mutation was 
confirmed by means of sequencing.
Quantification of PKA Activity in Intact Cells
Human embryonic kidney 293 cells were trans-
fected with the AKAR4-NES (a protein activity 
reporter 4 with a nuclear export signal) sensor24 
so that PKA activity could be monitored by means 
of fluorescence resonance energy transfer (FRET) 
imaging. Transfection and FRET imaging were 
performed as described previously.25 Equimolar 
concentrations of a cell-permeable pair of synergis-
tic cAMP analogues were used to activate PKA II.26
Quantification of PRKACA Protein  
and PKA Enzymatic Activity
Whole-cell or tissue lysates were studied for PKA 
Cα subunit expression by means of Western blot-
ting with the use of a specific antibody (sc-903, 
Santa Cruz Biotechnology). COS-7 cells were trans-
fected with the use of the X-tremeGENE HP DNA 
Transfection Reagent (Roche) and 500 ng of plas-
mid DNA per well for 24 hours. For transfections 
including both PKA Cα (nonmutant or Leu206Arg 
variant) and RIIβ subunits, a molar ratio of 1:8 
was used. In lysed cells from the transfection ex-
periments or patient-derived cells, PKA activity 
was determined by means of an enzymatic assay 
(Enzo Life Sciences).
Gene-Expression Microarray Analysis and Real-
Time Polymerase-Chain-Reaction (PCR) Analysis
An earlier microarray analysis of 22 adenomas27 
was expanded to include 39 adenomas in the cur-
rent study (see Table S1 in the Supplementary 
Appendix). For quantification of PRKACA expres-
sion, real-time quantitative PCR analysis was used. 
Details of the microarray experiments and real-
time PCR analysis are provided in the Supple-
men tary Appendix.
Statistical Analysis
Data were compared between two groups with 
the use of the Mann–Whitney U test and among 
three groups with the use of the Kruskal–Wallis 
test. All comparisons were two-sided, and P values 
of less than 0.05 were considered to indicate sta-
tistical significance. The analyses were performed 
with the use of SPSS software, version 20 (IBM).
R esult s
Somatic PRKACA Mutations and Germline 
Duplications in Cortisol-Producing Lesions
Exome sequencing was performed in samples 
from 10 patients with unilateral cortisol-producing 
adenomas and overt Cushing’s syndrome (Table S2 
in the Supplementary Appendix) and revealed a 
low number of somatic mutations per adenoma 
(median, 5; range, 1 to 14) (Table S3 in the Sup-
ple men tary Appendix). Within this small set of 
genetic alterations, somatic variants in PRKACA, 
encoding the PKA Cα subunit, were found in 
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8 of 10 tumors (c.617A→C, p.Leu206Arg in 7 and 
c.595_596insCAC, Leu199_Cys200insTrp in 1). The 
affected amino acids were highly conserved 
across a variety of species (Fig. S2 in the Sup ple-
mentary Appendix).
On the basis of these initial results, PRKACA was 
sequenced in 129 additional adenomas (including 
89 cortisol-producing, 20 aldosterone-producing, 
and 20 inactive adenomas). In 33 of these sam-
ples, the entire coding sequence was investigated, 
and in the remaining 96 samples, sequencing of 
hot-spot regions was performed. The Leu206Arg 
variant was identified in 14 of these 129 adeno-
mas, and all 14 patients with this variant also had 
overt Cushing’s syndrome, according to the pre-
defined criteria. Whole-exome and targeted se-
quencing indicated that both the nonmutated 
and mutated alleles were present in tumor tis-
sue, consistent with a heterozygous state of 
PRKACA mutations (Fig. 1A and 1B, and Fig. S3 
in the Supplementary Appendix). In the affected 
patients, there were no PRKACA mutations in 
DNA derived from leukocytes (19 patients) or fat 
tissue (1 patient) or in adjacent normal adrenal 
tissue (6 patients).
Comparative genomic hybridization of sam-
ples from 35 patients with cortisol-secreting bi-
lateral adrenal hyperplasias and overt Cushing’s 
syndrome identified 5 patients (4 kindreds) with 
copy-number gains (duplications) of the genomic 
region on chromosome 19p that includes PRKACA 
(Fig. 1C, and Table S4 in the Supplementary Ap-
pendix). In one case, the defect was inherited: 
a mother and son, both carriers of the same 
PRKACA duplication, were affected by bilateral 
macronodular hyperplasia. In another case, that 
of a 3-year-old boy with Cushing’s syndrome due 
to bilateral micronodular hyperplasia, the defect 
was de novo, because neither parent carried the 
PRKACA duplication. No amplification of PRKACA 
was found in 24 cortisol-producing adrenal ade-
nomas analyzed by means of single-nucleotide 
polymorphism array profiling.28
No PRKACA mutations were detected in 1600 
in-house exomes or in the 1000 Genomes Project 
data set (version 0.0.14). Although PRKACA dupli-
cations are reported in public databases of copy-
number variants in at least six instances (occurring 
in patients referred for genetic testing because of 
developmental delay), no PRKACA whole-gene du-
plications are included in the Database of Genomic 
Variants, which is based on the general population. 
Moreover, no PRKACA duplications were found in 
2000 persons with intellectual disability, congeni-
tal malformations, or both in an internal database.
PRKACA Mutations and Regulation  
of Catalytic Subunits by Regulatory Subunits
Analysis of the mouse full-length tetrameric 
RIIβ(2):Cα(2) holoenzyme structure23 revealed that 
this mutation is located in the highly conserved core 
of the interaction between the regulatory (RIIβ) 
and catalytic (Cα) subunits of PKA — a finding that 
supports a functional relevance of the Leu206Arg 
variant. Leu206 is part of the active-site cleft of the 
catalytic subunit to which the inhibitory sequence 
of the regulatory subunit binds, mimicking a sub-
strate for the catalytic subunit. This interaction 
keeps the catalytic subunit inactive in the absence 
of cAMP. Exchanging Leu206 with the bulky and 
positively charged amino acid Arg in silico yields 
steric hindrance between the side chain of the 
mutated Arg206 in the Cα subunit and Val115 
and Tyr228 in the RIIβ subunit (Fig. 2A and 2B).29
The functional consequences of the two detected 
variants (Leu206Arg and Leu199_Cys200insTrp) 
were investigated in intact cells by means of FRET 
microscopy with the use of a sensor for PKA 
activity (AKAR4-NES).24 The PKA activity in cells 
transfected only with either nonmutant Cα or the 
variants was high and was not further stimulated 
by cAMP analogues, indicating preservation of 
the catalytic activity in the mutants (Fig. 2C, and 
Fig. S4A and S4C in the Supplementary Ap pen-
dix). However, after cotransfection with excess 
nonmutant RIIβ, basal PKA activity was de-
creased in cells transfected with nonmutant Cα 
and became responsive to cAMP analogues, 
whereas PKA activity in the cells transfected 
with the mutants remained high and was not re-
sponsive to cAMP analogues (Fig. 2C, and Fig. S4B 
and S4D in the Supplementary Appendix). This 
finding indicates that the mutations made the 
catalytic subunit resistant to the physiologic sup-
pression by the regulatory subunit. The lack of 
suppression remained when an equal amount of 
nonmutant Cα was cotransfected, indicating a 
dominant effect of the mutations (Fig. 2D).
Similarly, transfection of the mutant Cα 
Leu206Arg variant caused a profound increase in 
PKA activity under basal conditions so that PKA 
activity was in the same range as that in cells 
The New England Journal of Medicine 
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transfected with the nonmutant Cα on cAMP 
stimulation, and this activity was not suppressed 
by cotransfection with RIIβ, indicating again a 
lack of suppression of the activity of the mutant 
catalytic subunit by the regulatory subunit (Fig. 2E). 
Consistent with these findings, basal PKA activ-
ity in tumor tissue was found to be higher in 
adenoma samples with PRKACA mutations than 
in those without such mutations (Fig. S5 in the 
Supplementary Appendix). Taken together, these 
data indicate that the Leu206Arg mutant protein 
is constitutively active and is not suppressed by 
the regulatory subunit.
association of Germline Duplication of PRKACA 
with Increased Protein Levels and PKA Activity
As compared with tumor-tissue samples from 
patients without any known genetic defects, tumor-
tissue samples from patients with duplications of 
PRKACA had higher PKA Cα messenger RNA and 
protein levels (Fig. S6A and S6B, respectively, in the 
Supplementary Appendix). Immuno histo chem-
ical experiments confirmed higher expression of 
the PKA Cα subunit in adrenal tissue from these 
patients (Fig. S6C in the Supplementary Ap pen-
dix). The higher expression of the PKA Cα subunit 
was associated with higher basal and cAMP-
C
A B
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Figure 1. Identification of Somatic PRKACA Mutation and Germline Genetic Duplications.
Panel A shows a sequence chromatogram of normal adrenal tissue, and Panel B a chromatogram of a cortisol- 
producing adrenal adenoma. A somatic mutation in PRKACA (c.617A→C) was identified in the cortisol-producing 
adenoma, resulting in a Leu206Arg substitution that is not present in the adjacent normal tissue. Panel C shows an 
ideogram of chromosome 19 (top) with the genes included in the p13.2–p13.12 band (GRCh37/h19). The black 
blocks (bottom) represent the size and position of the duplications. The gray blocks represent the genes included 
only in the shared region of duplication. The red block represents PRKACA.
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stimulated PKA activity (Fig. S6D in the Supple-
mentary Appendix).
Clinical Phenotypes and PRKACA Mutation Status
Whereas 22 of 59 patients (37%) with overt Cush-
ing’s syndrome due to a unilateral adenoma har-
bored a PRKACA mutation, this alteration was not 
present in any adenoma associated with subclini-
cal Cushing’s syndrome (40 patients), nor was it 
present in inactive adrenal adenomas (20 patients), 
aldosterone-producing adrenal adenomas (20 pa-
tients), or adrenocortical carcinomas (42 patients) 
or in adrenal tissue (10 patients) or lymphocytic 
DNA (35 patients) from patients with corticotropin-
independent adrenal hyperplasia (35 patients). 
Furthermore, in the group of patients with overt 
Cushing’s syndrome, the presence of PRKACA mu-
tations was associated with a more severe pheno-
type (Table 1). Accordingly, expression levels of a 
variety of steroidogenic enzymes in mutant ade-
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noma tissues were higher in the presence of a 
PRKACA mutation (Table S5 in the Supplementary 
Appendix).
There were no obvious phenotypic differences 
between patients with germline PRKACA duplica-
tions and those without duplications, although 
the number of patients with duplications was 
small. The affected mother and son had mild 
Cushing’s syndrome of insidious onset, caused 
by bilateral macronodular hyperplasia manifest-
ing in the third and fourth decade of life. The 
three young boys presenting with Cushing’s 
syndrome due to bilateral hyperplasia (two with 
micronodular disease and one with macronodular 
disease) (Table S4 in the Supplementary Appen-
dix) had severe disease similar to that of patients 
with somatic PRKACA mutations. One patient 
with PRKACA duplication had a paradoxical in-
crease in cortisol secretion after administration 
of dexamethasone,30 whereas the other four pa-
tients did not undergo a long-term dexamethasone 
suppression test (Liddle’s test) before surgery.
Discussion
Despite evidence that enhanced cAMP signaling 
is the culprit in many benign adrenal lesions 
leading to Cushing’s syndrome,8,18 the search for 
tumorigenic mutations in adrenal adenomas 
with the use of a candidate-gene approach has 
revealed only very rare mutations in a distinct 
subgroup of patients.12,13,17,31 The current study 
suggests that more than one third of cortisol-
producing adenomas associated with overt Cush-
ing’s syndrome have unique somatic mutations 
in PRKACA (which encodes the main catalytic 
subunit of PKA), resulting in constitutive PKA ac-
tivation. Although the mutation is present only in 
tumor cells in these patients, germline duplication 
of PRKACA was identified in a group of patients 
with bilateral adrenal hyperplasias. Consistent with 
the hypothesis that the resulting increased PKA 
activity is responsible for adrenocortical tumor 
formation, patients with somatic defects had 
single adenomas, whereas patients with germ-
line duplications presented with bilateral adrenal 
hyperplasias. All the patients with PRKACA de-
fects, whether germline or somatic, had overt 
Cushing’s syndrome, and none of the patients 
with subclinical Cushing’s syndrome or other ad-
renal tumors had genetic PRKACA alterations.
Thus, our findings provide evidence that 
PRKACA activation leads to marked excess of cor-
tisol, as one would expect from constitutive activa-
tion of the enzymes that mediate corticotropin-
dependent effects on adrenal steroidogenesis. The 
findings also indicate that subclinical Cushing’s 
syndrome is not an early form of overt disease 
but a pathophysiologically distinct entity. Because 
PRKACA mediates most of the effects of inacti-
vating PRKAR1A mutations32 and because muta-
tions of PRKAR1A are associated with a variety of 
tumors in humans and mice,33,34 we would specu-
late that somatic PRKACA defects might also play 
a role in other forms of endocrine and nonendo-
crine tumors.
PKA, a cAMP-dependent serine–threonine ki-
nase, is perhaps the best characterized protein 
Figure 2 (facing page). Functional Characterization  
of PRKACA Variants.
Panel A shows the structure derived from the protein 
kinase A (PKA) tetramer, with the nonmutant catalytic 
subunit (Cα) depicted in green and the regulatory sub-
unit (RIIβ) depicted in red. A zoomed view into the re-
gion of Leu206 in the Cα subunit is shown. Leu206 is 
depicted as a space-filling representation; the two resi-
dues in close proximity (Val115 and Tyr228) and addi-
tional residues from the inhibitory site (Arg111–Ser114, 
marked with an asterisk) of the regulatory subunit are 
depicted as sticks. Panel B shows the same region of 
the PKA tetramer, with Leu206 in the Cα subunit re-
placed by Arg206, also depicted as a space-filling rep-
resentation. Panel C shows PKA activity of nonmutant 
and mutant PKA Cα subunits transfected in human 
embryonic kidney 293 cells, as determined by means of 
fluorescence resonance energy transfer (FRET) assay 
with a PKA reporter (for details, see Fig. S4 in the Sup-
plementary Appendix). The results indicate that the mu-
tant variants are constitutively active. Asterisks indicate 
P<0.05 for the comparison with Cαnonmutant + RIIβ. 
AKAR4-NES denotes a protein activity reporter 4 with 
a nuclear export signal. Panel D shows that high con-
stitutive PKA activity was maintained when either mu-
tant was cotransfected with an equal amount of non-
mutant Cα subunit. Asterisks indicate P<0.05 for the 
comparison with Cαnonmutant + RIIβ. The data in Panels 
C and D were compared by means of a two-way analy-
sis of variance followed by Bonferroni’s test. Panel E 
shows the quantification of enzymatic PKA activity; 
COS-7 cells were transfected with Cα (nonmutant or 
mutant) and RIIβ, with or without the addition of cyclic 
AMP (cAMP). Asterisks indicate P<0.05 for the com-
parison between samples with and those without the 
addition of cAMP. The hatch mark indicates P<0.05 for 
the comparison between samples transfected with 
nonmutant Cα subunit and those transfected with mu-
tant Cα subunit without the addition of cAMP. In Pan-
els C, D, and E, the I bars represent the standard error.
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kinase and provides a clear example of allosteric 
regulation.35 In its inactive state, it is a tetra-
meric holoenzyme consisting of a dimer of two 
regulatory and two catalytic subunits; under 
physiologic conditions, PKA activity is induced by 
G-protein–coupled receptors through increased 
levels of cAMP.23,35 On binding of cAMP, the 
regulatory subunits dissociate from the catalytic 
subunits, allowing the enzyme to become ac-
tive.35 Although some randomly introduced mu-
tations in PRKACA have been shown to result in 
unopposed catalytic activation in vitro,36 such 
alterations have not been linked to human dis-
ease. The only naturally found gain-of-function 
PRKACA mutations are those described in the 
Cos1(A1) drosophila mutant.37 The two PRKACA 
mutants identified in the current study alter the 
structure of the catalytic subunit at a site that is 
essential for interaction with the regulatory sub-
unit, thus maintaining high activity of the cata-
lytic subunit in the absence of cAMP.23,35 The 
critical position of the Leu206Arg mutation at 
the core of the interaction between the catalytic 
subunit and the inhibitory site of the regulatory 
subunit, combined with the steric hindrance 
involving Val115 and Tyr228 in the regulatory 
subunit, may explain the high grade of specific-
ity of this particular mutation.
In conclusion, the current study links genetic 
variants of the main catalytic subunit of PKA 
with both hyperplasias and adenomas of the 
adrenal cortex leading to corticotropin-indepen-
dent Cushing’s syndrome. These observations 
are consistent with the known role of the cAMP 
signaling pathway in adrenal lesions that have 
been associated with Cushing’s syndrome.
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